Last reviewed · How we verify
NCT05342285
Flow Mediated Dilation in Association With Hyperuricemia
trial testing Flow mediated dilation in SLE in 60 participants. Status unknown.
27 December 2022
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 July 2022 |
| Primary completion | 27 December 2022 |
| Estimated completion | 27 December 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Flow mediated dilation
Conditions studied
- SLE — all drugs for SLE →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Atherosclerosis — all drugs for Atherosclerosis →
Sponsor
Assiut University
Who can join
Adults 18 to 45, female only, with SLE or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation. evaluate the role of uric acid as independent marker of cardiovascular risk in systemic lupus patient
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05342285
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Flow mediated dilation
Trials testing the same drug.
- NCT05492071 — Impact of Regional Vibration Application and Flow Mediated Dilation on Brachial Artery Hemodynamics · NA · completed
- NCT03776331 — Vascular Functions in Myeloma Patients During Anti-tumor Therapy · unknown
Other recruiting trials for SLE
Currently open trials in the same condition.
- NCT07203404 — A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. · EARLY_PHASE1 · recruiting
- NCT06839976 — CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus · Phase 1, PHASE2 · recruiting
- NCT06775912 — Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07148115 — Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus · recruiting
- NCT05822219 — Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases · NA · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05342285 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05342285.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing